LGC and Pharmidex form strategic alliance
LGC and Pharmidex, the London-based neuroscience research service provider, have formed a strategic alliance that raises the standard for DMPK (Drug metabolism and Pharmacokinetics) screening services to drug discovery companies.
Factors related to DMPK - the science of how molecules are broken down by the body and how long they stay in the bloodstream - are the major contributors to compound attrition. For this reason a reliable DMPK profile of compounds early in the drug discovery cycle is essential - it has the potential to save time, eliminate waste and thus add value to the drug discovery process.
By bringing together the world class bioanalytical capabilities of LGC with the pharmacology and drug discovery expertise of Pharmidex, the alliance will deliver a breadth and depth of DMPK service which will be hard to match. The partnership provides drug discovery companies with a very comprehensive offering - in silico, in vitro and beyond - across the whole drug discovery value chain, and is backed by a level of knowledge that is not commonly available in service companies.
Other news from the department business & finance
These products might interest you
Good Weighing Practice by Mettler-Toledo
Your Concrete Weighing Quality Assurance Plan
GWP Verification service
Milli-Q® Services / MyMilli-Q™ by Merck
Services & Support for Water Purification Systems
Quality Care, Delivered. In Person & Online
